Clinical trial
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to…
NCT00310635 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00310635 |
|---|---|
| Title | Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age |
| Official title | A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Vaccines Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Meningococcal Infection |
| Intervention type | Biological |
| Interventions | Meningococcal C conjugate vaccine |
| Enrollment | 241 |
| Start date | Jun 1, 2005 |
| First posted | Apr 4, 2006 |
| Last update posted | Oct 26, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: